Skip to main content

Table 3 Univariate analysis results of overall survival in 97 locally advanced esophageal squamous cell carcinoma patients who received curative concurrent chemoradiotherapy

From: The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy

Characteristics No. of patients Median OS (months) P value
Age
  < 60 years 64 (66%) 17.3 0.09
  ≥ 60 years 33 (34%) 13.1  
T status
 1 + 2 15 (16%) 19.3 0.30
 3 + 4 82 (84%) 13.6  
N status
 0 + 1 32 (33%) 25.5 0.021a
 2 + 3 65 (67%) 12.9  
Stage
 II + IIIA + IIIB 31 (32%) 19.3 0.47
 IIIC 66 (68%) 13.1  
Grade
 1 + 2 71 (73%) 15.6 0.76
 3 26 (27%) 13.6  
Location
 Upper 40 (41%) 19.3 0.42
 Middle + Lower 57 (59%) 13.2  
VEGF Day 0 (Mean: 176 pg/mL)
  < 80 33 (34%) 15.0 0.52
  > 80 64 (66%) 15.6  
VEGF Day 5 (Mean: 163 pg/mL)
  < 80 33 (34%) 22.6 0.06
  > 80 64 (66%) 12.0  
VEGF Day 28 (Mean: 195 pg/mL)
  < 80 29 (30%) 21.3 0.029a
  > 80 68 (70%) 12.8  
VEGF Day 5/Day 0 ratio
  < 1 52 (54%) 19.3 0.026a
  > 1 45 (46%) 12.0  
VEGF Day 28/Day 0 ratio
  < 1 39 (40%) 12.9 0.43
  > 1 58 (60%) 17.6  
VEGF Day 28/Day 5 ratio
  < 1 45 (46%) 20.9 0.002a
  > 1 52 (54%) 8.6  
  1. OS overall survival; VEGF vascular endothelial growth factor; HR hazard ratio; CI confidence interval
  2. aStatistically significant